These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

296 related articles for article (PubMed ID: 8528836)

  • 1. Stability of ursodiol in an extemporaneously compounded oral liquid.
    Johnson CE; Nesbitt J
    Am J Health Syst Pharm; 1995 Aug; 52(16):1798-1800. PubMed ID: 8528836
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Stability of an extemporaneously compounded baclofen oral liquid.
    Johnson CE; Hart SM
    Am J Hosp Pharm; 1993 Nov; 50(11):2353-5. PubMed ID: 8266961
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stability of ursodiol 25 mg/mL in an extemporaneously prepared oral liquid.
    Mallett MS; Hagan RL; Peters DA
    Am J Health Syst Pharm; 1997 Jun; 54(12):1401-4. PubMed ID: 9194984
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stability of an extemporaneously compounded clonidine hydrochloride oral liquid.
    Levinson ML; Johnson CE
    Am J Hosp Pharm; 1992 Jan; 49(1):122-5. PubMed ID: 1570852
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Stability of isradipine in an extemporaneously compounded oral liquid.
    MacDonald JL; Johnson CE; Jacobson P
    Am J Hosp Pharm; 1994 Oct; 51(19):2409-11. PubMed ID: 7847406
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Stability of an extemporaneously compounded terbutaline sulfate oral liquid.
    Horner RK; Johnson CE
    Am J Hosp Pharm; 1991 Feb; 48(2):293-5. PubMed ID: 2003504
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Stability of itraconazole in an extemporaneously compounded oral liquid.
    Jacobson PA; Johnson CE; Walters JR
    Am J Health Syst Pharm; 1995 Jan; 52(2):189-91. PubMed ID: 12879547
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Stability of Compounded Ursodiol Suspensions in PCCA Base, SuspendIt.
    Pramar YV; Mandal TK; Bostanian LA; Nguyen AT; Miller V; Morris TC; Graves RA
    Int J Pharm Compd; 2019; 23(1):70-76. PubMed ID: 30668538
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Stability of tacrolimus in an extemporaneously compounded oral liquid.
    Jacobson PA; Johnson CE; West NJ; Foster JA
    Am J Health Syst Pharm; 1997 Jan; 54(2):178-80. PubMed ID: 9117806
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Stability of levofloxacin in an extemporaneously compounded oral liquid.
    VandenBussche HL; Johnson CE; Fontana EM; Meram JM
    Am J Health Syst Pharm; 1999 Nov; 56(22):2316-8. PubMed ID: 10582824
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Stability of zonisamide in extemporaneously compounded oral suspensions.
    Abobo CV; Wei B; Liang D
    Am J Health Syst Pharm; 2009 Jun; 66(12):1105-9. PubMed ID: 19498126
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Stability of norfloxacin in an extemporaneously prepared oral liquid.
    Johnson CE; Price J; Hession JM
    Am J Health Syst Pharm; 2001 Apr; 58(7):577-9. PubMed ID: 11296605
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Stability of ciprofloxacin in an extemporaneous oral liquid dosage form.
    Johnson CE; Wong DV; Hoppe HL; Bhatt-Mehta V
    Int J Pharm Compd; 1998; 2(4):314-7. PubMed ID: 23989641
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Stability of extemporaneously prepared rifaximin oral suspensions.
    Cober MP; Johnson CE; Lee J; Currie K
    Am J Health Syst Pharm; 2010 Feb; 67(4):287-9. PubMed ID: 20133533
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Stability of extemporaneously compounded spironolactone suspensions.
    Mathur LK; Wickman A
    Am J Hosp Pharm; 1989 Oct; 46(10):2040-2. PubMed ID: 2816959
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Stability of extemporaneously prepared glycopyrrolate oral suspensions.
    Cober MP; Johnson CE; Sudekum D; Penprase K
    Am J Health Syst Pharm; 2011 May; 68(9):843-5. PubMed ID: 21515869
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Stability of extemporaneously prepared moxifloxacin oral suspensions.
    Hutchinson DJ; Johnson CE; Klein KC
    Am J Health Syst Pharm; 2009 Apr; 66(7):665-7. PubMed ID: 19299374
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Stability of an extemporaneously prepared thalidomide suspension.
    Kraft S; Johnson CE; Tyler RP
    Am J Health Syst Pharm; 2012 Jan; 69(1):56-8. PubMed ID: 22180553
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Stability of an extemporaneously compounded minoxidil oral suspension.
    Song Y; Chin ZW; Ellis D; Lwin EMP; Turner S; Williams D; Garg S
    Am J Health Syst Pharm; 2018 Mar; 75(5):309-315. PubMed ID: 29472513
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stability of extemporaneously prepared oxandrolone oral suspensions.
    Johnson CE; Cober MP; Hawkins KA; Julian JD
    Am J Health Syst Pharm; 2011 Mar; 68(6):519-21. PubMed ID: 21378300
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.